Savara Inc — Cash Flow (NASDAQ:SVRA) | MetaTrader

Open full chart

Financials

Overview 明細書 Statistics Dividends

Quarterly Annual

Cash from operating activities 39.8 M40.1 M34.6 M51.1 M89.1 M 99.29 M Cash from investing activities 9.05 M69.46 M52.65 M57.12 M39.94 M 57.23 M Cash from financing activities 3.69 M120.81 M87 K82.78 M117.58 M 1.4 M Free cash flow 39.75 M40.04 M34.59 M50.8 M89.08 M 99.28 M

ニュース

Hercules Capital director Fallon buys $149,800 in shares

Citizens reiterates Savara stock rating on likely FDA approval

FDAがSavaraの希少肺疾患治療薬申請を受理

FDA accepts Savara’s drug application for rare lung disease

ハーキュリーズ・キャピタル、2025年第4四半期の暫定業績とNAV増加を報告

Hercules Capital reports preliminary Q4 2025 financial results and NAV increase

サバラ、新薬発売に向け追加7500万ドルの負債融資を確保

サバラ社、最大1億500万ドルのタームローンにアクセスするために融資契約を修正

Savara Inc. (SVRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Savaraの株価、BLA再提出でGuggenheimがBuy評価を維持し上昇

Savara stock advances as Guggenheim reiterates Buy rating on BLA resubmission

H.C. ワインライト、Savaraの株価目標を8ドルから10ドルに引き上げ